Skip to content
Orasis
Search
Close
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Our Solution
    • About Presbyopia
    • CSF-1 Overview
    • Mechanism of Action
  • News and Events
  • CONTACT
Menu
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Our Solution
    • About Presbyopia
    • CSF-1 Overview
    • Mechanism of Action
  • News and Events
  • CONTACT

Orasis Pharmaceuticals Announces Initiation of Phase 3 Clinical Studies of Novel Eye Drop Candidate for the Treatment of Presbyopia

  • Post author:Julia Reznick
  • Post published:October 28, 2020
  • Post category:Press Releases

HERZLIYA, Israel, October 28, 2020 – Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the treatment of presbyopia symptoms, today announced the initiation…

Continue Reading Orasis Pharmaceuticals Announces Initiation of Phase 3 Clinical Studies of Novel Eye Drop Candidate for the Treatment of Presbyopia

Recent Posts

  • Orasis Pharmaceuticals Announces Initiation of Phase 3 Clinical Studies of Novel Eye Drop Candidate for the Treatment of Presbyopia
  • Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopia
  • Orasis Pharmaceuticals Announces CSF-1 Eye Drop Successfully Met Primary Endpoint in Phase 2b Clinical Study in Presbyopia
  • Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopia
  • Elad Kedar Featured on the Empowered Patient Podcast

Recent Comments

    Archives

    • October 2020
    • September 2020
    • October 2019
    • March 2019
    • December 2018
    • November 2018
    • October 2018
    • June 2018

    Categories

    • Press Releases
    • Events

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Orasis

    HOME

    ABOUT US

    • Company Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
    Menu
    • Company Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors

    OUR SOLUTION

    • About Presbyopia
    • CSF-1 Overview
    • Mechanism of Action
    Menu
    • About Presbyopia
    • CSF-1 Overview
    • Mechanism of Action

    NEWS AND EVENTS

    CONTACT

    Orasis

    12 Maskit St., Herzliya
    P.O.B. 12929, 4673312 Israel
    T: +972-9-8877745
    F: +972-9-8877746
    info@orasis-pharma.com

    Linkedin
    Site by TreeO Marketing    |   Developed by Foothold Systems